Min 11-13
"We believe that we have a really unique opportunity with a market that’s pretty highly consolidated, but very active for deal making. This is informing the new strategy that we’ve announced early last month, where we are focused on discovering and development of MagSense products. And rapid collaboration and partnership to enable continued advancement of the technology and access to novel MagSense drugs.
GE, Bayer, and Bracco dominate this market with a total of 75 percent of the revenue that’s delivered. Importantly, this is a space that For actually almost seven years now, the FDA has been pushing for the industry to get away from gadolinium based contrast agents. These are known to cause some incidents of renal cellular toxicity, even real failure.
And we have a unique platform within MagSense, leveraging our super paramagnetic iron oxide nanoparticles that are safe and are really a fantastic alternative. To gadolinium for clear visualization in MRI scans. Without any exposure to renal toxicity. Importantly, we see this as great step to now redefine the category of molecular imaging, where we can push molecular MRI to the state of the art.
MRI is already more than four times the global footprint installed base of PET scanners, which is the leading modality for molecular imaging right now. Importantly, the drugs that are delivered. For Pat scanning include a number of ionizing radiation, ionizing radiation isotopes, which are very hard to manage throughout the supply chain and very hard to manage through clinical implementation.
So, we see a great opportunity to drive forward our differentiated MagSense platform for MRI, molecular MRI, which should become the mainstay in molecular imaging going forward. Next slide, please. As I mentioned in this space, we are playing with some world class companies. We are definitely the David amongst the Goliaths in this space, which is exciting because we have something none of them do.
We’re the 1st mover to deliver molecular MRI. And so though we’re young, we’re mighty with a differentiated capability amongst this competitive landscape. And again, this is a landscape where the notion of innovation is. Thank you. Not quite the level of science that we’ve delivered in MagSense in the platform."
(20min delay)